Dr. O'Shaughnessy on Using Phosphoprotein Assays to Personalize Treatment for Breast Cancer

Video

In Partnership With:

Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses how the results of phosphoprotein assays can impact treatment decisions for select patients with advanced breast cancer.

Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses how the results of phosphoprotein assays can impact treatment decisions for select patients with advanced breast cancer.

Personalizing treatment for patients with triple-negative breast cancer (TNBC), as well as the heavily pretreated ER-positive subtype, has always been difficult for oncologists, O’Shaughnessy explains. Also, these groups are often diagnosed with widespread liver metastases. Researchers have sought to determine if the androgen receptor (AR) has a potential role in this occurrence.

Anecdotally, O’Shaughnessy discusses a patient with TNBC who did not carry the AR protein but did have high levels of phosphorylation of AR. Though the clinical implications of this are unclear, O’Shaughnessy predicts that AR is active in this case. In patients with liver metastases, oncologists often discover concentrated, high levels of phosphorylation of AR, which could be driving the PI3K pathway. This could help drive therapeutic strategies for these patients, O’Shaughnessy adds.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD